Skip to main content

Table 1 Baseline characteristics for the examined early rheumatoid arthritis patients. Results are given in mean (± standard deviation) for continuous variables and numbers (percentages) for categorical variables.

From: Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study

  Adalimumab +
Methotrexate
(N = 214)
Methotrexate
Monotherapy
(N = 188)
Demographic characteristics   
Age (years) 51.8 (14.3) 52.6 (13.2)
Female % 152 (71.0) 137 (72.9)
Clinical characteristics   
Disease duration (years) 0.7 (0.8) 0.8 (0.9)
Previously taken DMARDs % 69 (32.2) 56 (29.8)
Previously taken corticosteroids % 79 (36.9) 64 (34.0)
Tender joint count (0-66) 30.5 (14.6) 31.9 (14.3)
Swollen joint count (0-66) 21.4 (11.4) 22.5 (12.1)
C-reactive protein (mg/l) 40.2 (42.4) 40.4 (40.9)
HAQ (0-3) 1.5 (0.6) 1.5 (0.7)
DAS28 6.3 (0.9) 6.3 (0.9)
DXR-MCI (mg/cm2) 0.45 (0.09) 0.45 (0.09)
  1. DMARDs = disease modifying anti-rheumatic drugs; HAQ = Health Assessment Questionnaire; DAS28 = 28-joint disease activity score; DXR = Digital X-ray radiogrammetry; MCI = metacarpal cortical index.